Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28442161 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BP2RX7BACE1CTSK | |
| SCHEMBL9933255 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BP2RX7BACE1CTSK | |
| SCHEMBL9934458 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BP2RX7BACE1CTSK | |
| SCHEMBL20566873 | 0.90 | TGM2 (0.43) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL1440097 | 0.90 | TGM2 (0.43) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL1439945 | 0.90 | TGM2 (0.43) | ITGB3ITGA2BCTSKCTSLCTSS | |
| SCHEMBL25889247 | 0.75 | YAP1 (0.52) | ITGB3ITGA2BP2RX7CTSKCTSL | |
| SCHEMBL29782573 | 0.75 | USP30 (0.55) | USP30PRMT5JAK2JAK1 | |
| SCHEMBL883610 | 0.75 | USP30 (0.55) | USP30PRMT5JAK2JAK1 | |
| SCHEMBL9932890 | 0.75 | STS (0.37) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-07-25 | — | — | US | disclosed |
| CN-112300172-B | Bruton tyrosine kinase inhibitors | 比奥根MA公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| CN-112300172-A | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-107011330-B | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2020-07-03 | — | — | CN | disclosed |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3461824-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3461824-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Biogen MA Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-2473049-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-9790229-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9249146-B2 | Bruton'S tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-10-16 | — | — | US | disclosed |
| US-8785440-B2 | Bruton's tyrosine kinase inhibitors | BIOGEN IDEC MA, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
| US-20160376281-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
| US-20140309212-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
| US-20120157443-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ITGB3 1674/4885ITGA2B 2040/4885P2RX7 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.